Physiological levels of estradiol stimulate plasma high density lipoprotein2 cholesterol levels in normal men
Date
relationships.isAuthorOf
Bremner, William J.
Rivier, Jean E.
Bagatell, Carrie J.
Knopp, Robert H.
Journal Title
Journal ISSN
Volume Title
Publisher
Endocrine Society
Abstract
Premenopausal women have a lower risk of coronary artery disease than men
or postmenopausal women; estrogens are thought to contribute to this lower
risk. Administration of exogenous estrogen to post-menopausal women
increases plasma high density lipoprotein (HDL) cholesterol and may reduce
mortality from coronary disease in users. Although many investigations
have examined the roles of estrogen in the regulation of lipoproteins in
women, little attention has been directed to estrogen regulation of lipids
in men. We designed a paradigm to study the role of physiological levels
of estradiol (E2) on plasma lipoproteins in healthy men. We used a GnRH
antagonist, Nal-Glu, to suppress endogenous steroid hormones in healthy
men. We then administered testosterone (T) enanthate (100 mg, im, weekly)
to restore T levels to the baseline range, and we administered an
aromatase inhibitor, testolactone (Teslac), to prevent the normal
conversion of T to E2, thereby producing a selective estrogen deficiency
state in normal young men. As controls, we administered Nal-Glu and T
along with placebo Teslac to a separate group of men; a third group of men
received all placebo medications. We found that in men who received
Nal-Glu plus T plus Teslac, E2 levels were profoundly suppressed during
treatment, whereas T levels remained in the baseline range. Plasma HDL
cholesterol, particularly, the HDL2 fraction, decreased significantly in
response to the low serum E2 level. Plasma apoprotein-AI levels also
decreased significantly. Plasma LDL and triglyceride levels did not
change. All hormone and lipoprotein parameters returned to baseline within
4 weeks after treatment ended. In men who received Nal-Glu plus T, plasma
HDL and apoprotein-AI decreased, but these decreases did not achieve
statistical significance. Only a small decrease in HDL2 cholesterol was
seen in these men. There were no hormonal or lipid changes in the placebo
group. We conclude that in men, physiological levels of E2 are important
in maintaining plasma levels of HDL cholesterol, especially the HDL2
fraction. These observations suggest that estrogen, in the amount normally
produced in men, may offer some degree of protection against
cardiovascular disease in males, as they do in women.
Description
Citation
J Clin Endocrinol Metab. 1994 Apr;78(4):855-61
